A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
Clinical Trial Grant
Awarded By
Celgene Corporation
Start Date
October 12, 2023
End Date
October 14, 2028
Awarded By
Celgene Corporation
Start Date
October 12, 2023
End Date
October 14, 2028